AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 302 min read$QURE

Abi-Saab Walid sold $67K of QURE

Abi-Saab Walid (Chief Medical Officer) sold 1,434 shares of uniQure N.V. (QURE) at $46.86 on 2026-06-26.

Original reporting
SEC EDGAR · Abi-Saab Walid
Published Jun 30, 2026, 9:06 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 30, 2026, 9:10 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$QURE
Neutral
high confidence
Mentioned
$QURE
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$QURENeutralLow
01

Why it matters

The newest fact is the CMO’s open-market sale details (shares, price, total value) and post-transaction holdings; it does not include any new operational or financial guidance.

02

Market read

Traders may note insider selling as a sentiment datapoint, but there is no fundamental catalyst to drive repricing.

03

What to watch

No 10b5-1 plan is cited, but the article also lacks any follow-on buys, option exercises, or changes in broader insider ownership trends.

Relevance 3/10Novelty 3/10Timing: SEC Form 4 filed 2026-06-30; sale executed 2026-06-26.

Background

The article is an SEC Form 4 insider transaction disclosure for uniQure N.V. (QURE).

Company-level read

Ticker impact

$QURENeutralHigh confidence
Context

uniQure N.V. insider Form 4 shows CMO Abi-Saab Walid sold 1,434 shares at $46.86 on 2026-06-26.

Expected impact

Low likelihood of a sustained price move; any reaction is likely short-lived and sentiment-driven.

Evidence & confidence

The filing is a disclosed sale by an officer, but it provides no new company fundamentals, guidance, or material corporate event.

Market effects

Sector

Minimal—single-company insider transaction without sector-wide catalyst.

Regional

None indicated; filing is company-specific.

Global

None indicated; no deal/regulatory/clinical catalyst mentioned.

Counterpoint

What could challenge this read

The sale could reflect diversification or personal liquidity needs rather than negative expectations, especially with a small absolute value relative to typical institutional flows.

Key entities

  • issuer
    uniQure N.V.

    Company whose insider transaction is disclosed via SEC Form 4.

  • insider
    Abi-Saab Walid

    Chief Medical Officer who sold shares in an open-market transaction.

Read at source← All news

Related articles

AUG 8
$QUREMed

uniQure (QURE) Q2 2026 Earnings Call Transcript

uniQure (NASDAQ:QURE) reported Q2 2026 results and said the FDA aligned on submitting a Huntington’s disease AMT-130 BLA under accelerated approval in Q3 2026 using three-year data. Cash and investments were $810.3M at June 30, 2026 after a $259M follow-on. Q2 revenue was $5.8M, net loss $81.1M.

aol.com8 min
AUG 6
$QUREMed

Gene therapy shows benefits in all participants in Fabry clinical trial

uniQure said its investigational one-time gene therapy AMT-191 boosted alpha-galactosidase A levels in all 11 Fabry patients dosed in a Phase 1/2 U.S. trial (NCT06270316). All participants stopped enzyme replacement therapy. The company reported a manageable safety profile as of June, after prior liver enzyme elevations in two patients resolved with immunosuppression.

fabrydiseasenews.com5 min
JUL 29
$QUREMedAI 8/10

Why is uniQure stock surging today? By Investing.com

uniQure NV (QURE) shares rose about 6.3% pre-market after the company reported 2Q 2026 results and received July 2026 FDA meeting minutes confirming alignment that an AMT-130 BLA submission under accelerated approval using existing clinical data is reasonable. Revenue was $5.84M vs ~$5.49M consensus. uniQure also raised $259M via follow-on offering, extending cash runway to 2030.

investing.com6 min
JUL 29
$QUREMedAI 8/10

uniQure Inc.: uniQure Announces Second Quarter 2026 Financial Results and Provides Company Update

uniQure N.V. (NASDAQ: QURE) reported Q2 2026 results and updated its gene therapy pipeline. It said FDA alignment supports a Q3 2026 BLA submission for AMT-130 in Huntington’s disease, with four-year Phase I/II data planned for September 2026. For AMT-260, early Phase I/IIa cohort data showed seizure reductions and no AMT-260 related SAEs. uniQure raised $259M via a follow-on offering, extending cash runway into 2030. Q2 revenue was $5.8M.

finanznachrichten.de6 min
JUL 29
$QUREMed

uniQure N.V. (QURE): Results of Operations and Financial Condition

uniQure N.V. (QURE) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 qure-20260729xex99d1.htm EX-99.1 Exhibit 99.1 uniQure Announces Second Quarter 2026 Financial Results and Provides Company Update ~ U.S. and U.K. regulatory submissions for AMT-130 for Huntington’s disease on track as planned for the third quarter of 2026 ~ ~ Topline fo

SEC EDGAR 8-K6 min
JUN 25
$QUREMedAI 8/10

uniQure Inc.: uniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares

uniQure N.V. (Nasdaq: QURE) said it closed an upsized underwritten public offering of 5,686,813 ordinary shares at $45.50 each, including 741,758 shares from full exercise of the underwriters’ option. Gross proceeds were about $259 million before underwriting fees and expenses. Net proceeds will fund AMT-130 commercialization readiness, a confirmatory study, other clinical programs, business development, and general corporate purposes.

finanznachrichten.de2 min